Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease

Molecules - Switzerland
doi 10.3390/molecules24244551
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Current, Emerging, and Anticipated Therapies for Sickle Cell Disease

Mayo Clinic Proceedings
Medicine
2018English

Cell-Based Therapies for Huntington's Disease

Drug Discovery Today
Drug DiscoveryPharmacology
2014English

Toward Peptide-Based Inhibitors as Therapies for Parkinson's Disease

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2015English

Rational Design of Peptide-Based HIV Proteinase Inhibitors

Science
MultidisciplinaryPhilosophy of ScienceHistory
1990English

The Sickle Cell Disease Implementation Consortium: Translating Evidence-Based Guidelines Into Practice for Sickle Cell Disease

American Journal of Hematology
Hematology
2018English

Rifaximin for Sickle Cell Disease

American Journal of Hematology
Hematology
2019English

Proceedings: Moving Toward Cell-Based Therapies for Heart Disease

Stem cells translational medicine
MedicineDevelopmental BiologyCell Biology
2015English

Sickle Cell Disease

Revista Brasileira de Hematologia e Hemoterapia
2011English

Harnessing the Power of Human Tumor-Derived Cell Lines for the Rational Design of Cancer Therapies

Pigment Cell and Melanoma Research
BiochemistryDermatologyOncologyGeneticsMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy